GenScript Launches Hybridoma Stabilization Service
May 20, 2010
PISCATAWAY, N.J., May 20, 2010- Internationally recognized biology contract research organization GenScript USA Inc. has launched Hybridoma Stabilization service that produces a permanent source of antibody.
Antibody production by hybridoma cell lines is inherently unstable. Improper maintenance of cell line may diminish antibody productivity and eventually results in loss of the cell line itself. Traditional hybridoma stabilization that relies on the selection of stable clones for extended stable expression does not solve this problem. By integrating antibody engineering and bioprocess development technologies, GenScript’s advanced Hybridoma Revival System can redesign the antibody for permanent preservation with improved productivity, solving the inherent defect of antibody generation by hybridoma.
GenScript’s hybridoma stabilization service covers complete antibody sequencing, vector construction and plasmid preparation, transient expression evaluation, and stable cell line development. It delivers stable clones with high productivity of the desired antibody. In addition, customers can freely select original or novel Fc regions for the antibody.
GenScript is a contract research organization (CRO) specialized in biological research and drug discovery services. Its service portfolio includes bio-reagent services, assay development & screening, lead optimization, and antibody drug development. The renowned one-stop bioreagent services include custom gene synthesis and molecular biology, custom protein expression and purification, custom peptide synthesis, antibody production, and custom cell line development. Headquartered in Piscataway, New Jersey, GenScript has become a world-leading Biology CRO and the largest gene synthesis supplier in the USA, with subsidiaries in France, Japan, and China.
# # # #
For further information, please contact:
Executive Vice President
GENSCRIPT USA Inc.
Your Innovation Partner in Drug Discovery!